CJC-Family Component + Ipamorelin | Research Blend
RESEARCH BLEND

CJC-1295 + IPAMORELIN | MOLECULAR & ANALYTICAL RESEARCH

Modified GRF(1-29) + Ipamorelin — Component-Aware Research Blend
$109.00
Two-component laboratory research blend containing a CJC-family component and ipamorelin. Exact CJC component identity remains under scientific review. No combined mechanism, synergy, or efficacy is established. Research use only; not for human or veterinary use.
✓ Scientific Identity Established
⏳ Laboratory Testing In Progress
⏳ Batch Documentation Pending
✓ Research Use Only
✓ U.S. Fulfillment
In Laboratory Testing
Lot Verification Variant-specific documentation
Traceable Lots VBL lot identification
Primary Literature Peer-reviewed sources
Research Use Only Laboratory research materials

Scientific Specifications

Reference characteristics for this multi-component laboratory research material.

Chemical Identity — CAS · Molecular Formula · Molecular Weight
Not applicable — multi-component peptide blend

The governed scientific identity of each constituent is presented in the Components section below.

Research Classification
Research Use Only (RUO). Not for human or veterinary use.

Components

Governed scientific identity of each constituent of this multi-component research material, in specification order.

Component 1

CJC-1295 without DAC (Modified GRF 1-29)

CAS Number
863288-34-0
Molecular Formula
C152H252N44O42
Molecular Weight
3367.9
Research Classification
Research Use Only (RUO). Not for human or veterinary use.
Component 2

Ipamorelin

CAS Number
170851-70-4
Molecular Formula
C38H49N9O5
Molecular Weight
711.85
Storage
-20°C
Research Classification
Research Use Only (RUO). Not for human or veterinary use.

SCIENTIFIC OVERVIEW

Scientific background and research classification for this laboratory reference material.

This catalog item is a two-component laboratory reference mixture labeled CJC-1295 without DAC / Modified GRF(1-29) plus ipamorelin. The exact CJC component identity is conflicted across supplied records. No disputed CJC identity value or combined molecular identity is adopted here. Research use only.

Primary Research Category
Growth Hormone Research
Material Type
Lyophilized Peptide
Intended Use
Laboratory Research
Research Categories
Growth Hormone Axis Receptor Pharmacology

Mechanism of Action

Molecular interaction profile describing how this research material engages receptor systems and influences downstream biological signaling pathways.

No combined mechanism, interaction, compatibility, pharmacokinetic property, or efficacy is assigned. Component literature cannot resolve the conflicted CJC component or characterize the mixture.

Primary Organ Systems
  • Endocrine System

Research Documentation

Laboratory documentation is presented when available for the selected product specification and current lot.

In Laboratory Testing
Laboratory Documentation In Progress

Laboratory documentation for the current lot is being completed.

Scientific References
Peer-Reviewed Literature

Explore published literature, clinical investigations, and foundational scientific research.

View References →
Laboratory Resources
Technical Guidance

Storage guidance, handling recommendations, analytical methods, and laboratory best practices.

Related Research
Companion Materials

Discover complementary research materials frequently studied alongside this compound.

Research Center

Scientific literature, laboratory resources, and related materials curated to support research involving this research material.

Scientific References
Peer-Reviewed Literature

Explore curated publications from peer-reviewed journals including clinical investigations, mechanistic studies, and foundational scientific literature.

Browse References →
Scientific Dossier
Deeper Technical Treatment

Comprehensive scientific documentation including literature review, mechanism, pharmacology, and study data for this research material.

Laboratory Resources
Technical Guidance

Storage guidance, handling information, analytical standards, research policies, and laboratory support documentation.

Research Library

Curated peer-reviewed literature grouped by the scientific identity each source evidences.

CJC-1295 without DAC (Modified GRF 1-29) — Component Evidence

Clinical Trial•Journal of Clinical Endocrinology & Metabolism• 1994

Incorporation of D-Ala2 in growth hormone-releasing hormone-(1-29)-NH2 increases the half-life and decreases metabolic clearance in normal men

Contextual scaffold evidence for D-Ala2 GHRH(1-29); not the complete no-DAC tetrasubstituted peptide.
Velora Research Insight
Component/context evidence only; no exact-blend inference.
PubMed →DOI →
Analytical Study•Analytical and Bioanalytical Chemistry• 2016

Qualitative identification of growth hormone-releasing hormones in human plasma by means of immunoaffinity purification and LC-HRMS/MS

Analytical context for synthetic GHRH analog detection; no blend or efficacy claim.
Velora Research Insight
Component/context evidence only; no exact-blend inference.
PubMed →DOI →

Ipamorelin — Component Evidence

Pharmacology Study•European Journal of Endocrinology• 1998

Ipamorelin, the first selective growth hormone secretagogue

Primary component pharmacology describing ipamorelin selectivity and GH-secretagogue activity.
Velora Research Insight
Component/context evidence only; no exact-blend inference.
PubMed →DOI →
Clinical Trial•Pharmaceutical Research• 1999

Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers

Human component-only PK-PD modeling; not evidence for the blend or CJC component.
Velora Research Insight
Component/context evidence only; no exact-blend inference.
PubMed →DOI →